ASX:NOX Noxopharm (NOX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Noxopharm Stock (ASX:NOX) 30 days 90 days 365 days Advanced Chart Get Noxopharm alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.23 million shsAverage VolumeN/AMarket Capitalization$26.59 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNoxopharm Limited, a biotech company, discovers and develops treatments for cancer and inflammation, and mRNA vaccines in Australia. It primarily develops Veyonda, a formulation of idronoxil for the treatment of solid tumors. The company also develops LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions; and Sofra platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases. The company was incorporated in 2015 and is based in Glenhaven, Australia.Read More… Receive NOX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Noxopharm and its competitors with MarketBeat's FREE daily newsletter. Email Address NOX Stock News HeadlinesNoxopharm Secures $2.5 Million for Clinical Trials and R&DMay 19, 2025 | tipranks.comNoxopharm Unveils Promising SOF-SKN Data at Rheumatology ConferenceMay 5, 2025 | tipranks.comElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.May 27, 2025 | Brownstone Research (Ad)Noxopharm’s Lupus Drug Clears Final Preclinical HurdleApril 14, 2025 | tipranks.comNoxopharm Reports Half-Year Financial Results and Strategic FocusFebruary 24, 2025 | tipranks.comBargain Barrel: Four ASX cancer-fighting stocks with market caps under $35 millionFebruary 24, 2025 | msn.comNoxopharm jumps as flagship lupus drug clears first-pass in vitro safety testsFebruary 4, 2025 | msn.comNoxopharm Issues New Unquoted Equity SecuritiesJanuary 10, 2025 | tipranks.comSee More Headlines NOX Stock Analysis - Frequently Asked Questions How were Noxopharm's earnings last quarter? Noxopharm Limited (ASX:NOX) announced its earnings results on Thursday, February, 21st. The company reported ($0.04) earnings per share (EPS) for the quarter. Noxopharm had a negative trailing twelve-month return on equity of 59.29% and a negative net margin of 149.07%. What other stocks do shareholders of Noxopharm own? Based on aggregate information from My MarketBeat watchlists, some other companies that Noxopharm investors own include AMC Entertainment (AMC), Dimerix (DXB), Align Technology (ALGN), Aurora Cannabis (ACB), Bandwidth (BAND), Alteryx (AYX) and Axcella Health (AXLA). Company Calendar Last Earnings2/21/2019Today5/27/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:NOX CIKN/A Webwww.noxopharm.com Phone61 2 9144 2223FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.58 million Net Margins-149.07% Pretax MarginN/A Return on Equity-59.29% Return on Assets-34.01% Debt Debt-to-Equity RatioN/A Current Ratio3.83 Quick Ratio8.43 Sales & Book Value Annual Sales$2.40 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow15.42 Book ValueA$0.02 per share Price / BookN/AMiscellaneous Outstanding Shares292,240,000Free FloatN/AMarket Cap$26.59 million OptionableNot Optionable Beta0.78 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (ASX:NOX) was last updated on 5/27/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Noxopharm Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Noxopharm With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.